Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 901 AL 915

Endoplasmic reticulum-mitochondria signaling in neurons and neurodegenerative diseases

Markovinovic A, Greig J, Martín-Guerrero SM, Salam S, Paillusson S.

J Cell Sci. 2022 Feb 1;135(3):jcs248534. doi: 10.1242/jcs.248534. Epub 2022 Feb 7.

An insight into diagnosis of depression using machine learning techniques: a systematic review

Bhadra S, Kumar CJ.

Curr Med Res Opin. 2022 May;38(5):749-771. doi: 10.1080/03007995.2022.2038487. Epub 2022 Feb 17.

Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches

Bohnen NI, Yarnall AJ, Weil RS, Moro E, Moehle MS, Borghammer P, Bedard MA, Albin RL.

Lancet Neurol. 2022 Apr;21(4):381-392. doi: 10.1016/S1474-4422(21)00377-X. Epub 2022 Feb 4.

Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation

Arbo BD, Schimith LE, Goulart Dos Santos M, Hort MA.

Eur J Pharmacol. 2022 Mar 15;919:174800. doi: 10.1016/j.ejphar.2022.174800. Epub 2022 Feb 5.

Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology

Marotta NP, Lee VM.

Curr Opin Neurobiol. 2022 Feb;72:171-177. doi: 10.1016/j.conb.2022.01.003. Epub 2022 Feb 4.

Sleep duration, insomnia, and Parkinson disease

Henderson VW.

Menopause. 2022 Feb 7;29(3):251-252. doi: 10.1097/GME.0000000000001954.

Tremor as a symptom of degenerative cervical myelopathy: a systematic review

El Khoury M, Mowforth OD, El Khoury A, Partha-Sarathi C, Hirayama Y, Davies BM, Kotter MR.

Br J Neurosurg. 2022 Jun;36(3):340-345. doi: 10.1080/02688697.2022.2033701. Epub 2022 Feb 8.

Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches

Sharma VK, Singh TG, Prabhakar NK, Mannan A.

Neurochem Res. 2022 Jun;47(6):1459-1476. doi: 10.1007/s11064-022-03546-8. Epub 2022 Feb 8.

Embodied cognition in neurodegenerative disorders: What do we know so far? A narrative review focusing on the mirror neuron system and clinical applications

Maggio MG, Piazzitta D, Andaloro A, Latella D, Sciarrone F, Casella C, Naro A, Manuli A, Calabrò RS.

J Clin Neurosci. 2022 Apr;98:66-72. doi: 10.1016/j.jocn.2022.01.028. Epub 2022 Feb 5.

Efficacy of Wearable Device Gait Training on Parkinson's Disease: A Randomized Controlled Open-label Pilot Study

Kawashima N, Hasegawa K, Iijima M, Nagami K, Makimura T, Kumon A, Ohtsuki S.

Intern Med. 2022 Sep 1;61(17):2573-2580. doi: 10.2169/internalmedicine.8949-21. Epub 2022 Feb 8.

Striatal Synaptic Dysfunction in Dystonia and Levodopa-Induced Dyskinesia

Scarduzio M, Hess EJ, Standaert DG, Eskow Jaunarajs KL.

Neurobiol Dis. 2022 May;166:105650. doi: 10.1016/j.nbd.2022.105650. Epub 2022 Feb 6.

Novel frameshift CTSF mutation causing kufs disease type B mimicking frontotemporal dementia-parkinsonism

Gultekin M, Tufekcioglu Z, Baydemir R.

Neurocase. 2022 Feb;28(1):107-109. doi: 10.1080/13554794.2022.2038635. Epub 2022 Feb 9.

Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells

Kim J, Jeon J, Song B, Lee N, Ko S, Cha Y, Leblanc P, Seo H, Kim KS.

Nat Protoc. 2022 Mar;17(3):890-909. doi: 10.1038/s41596-021-00673-4. Epub 2022 Feb 9.

Immediate and long-term effects of speech treatment targets and intensive dosage on Parkinson's disease dysphonia and the speech motor network: Randomized controlled trial

Narayana S, Franklin C, Peterson E, Hunter EJ, Robin DA, Halpern A, Spielman J, Fox PT, Ramig LO.

Hum Brain Mapp. 2022 May;43(7):2328-2347. doi: 10.1002/hbm.25790. Epub 2022 Feb 10.

Astrocytes protect dopaminergic neurons against aminochrome neurotoxicity

Segura-Aguilar J, Mannervik B, Inzunza J, Varshney M, Nalvarte I, Muñoz P.

Neural Regen Res. 2022 Sep;17(9):1861-1866. doi: 10.4103/1673-5374.335690.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias